Septerna, Inc. (SEPN) – What Are Investment Firms Saying About This Stock?

Shares of Septerna, Inc. (NASDAQ:SEPN) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $52.44.

Several brokerages have recently issued reports on SEPN. Truist Financial boosted their price objective on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Guggenheim lifted their price target on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Stifel Nicolaus set a $49.00 price target on Septerna in a research report on Tuesday, August 11th. Wells Fargo & Company boosted their price target on Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, JPMorgan Chase & Co. increased their price objective on Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th.

Insider Buying and Selling at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 25,000 shares of Septerna stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $7,665,196. The trade was a 12.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daniel Long sold 3,334 shares of Septerna stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total transaction of $114,922.98. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,323,321.64. The trade was a 3.34% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 31,667 shares of company stock worth $1,341,010. Insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna during the 4th quarter worth about $88,000. The Manufacturers Life Insurance Company purchased a new stake in Septerna during the 2nd quarter worth approximately $211,000. Canada Pension Plan Investment Board purchased a new position in Septerna in the second quarter valued at $298,000. Seven Fleet Capital Management LP purchased a new position in shares of Septerna in the 4th quarter valued at about $319,000. Finally, Legal & General Group Plc acquired a new position in shares of Septerna during the second quarter worth $337,000.

Septerna Stock Up 3.1%

Shares of NASDAQ:SEPN opened at $37.45 on Friday. Septerna has a 52-week low of $17.55 and a 52-week high of $51.10. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -69.35 and a beta of 2.29. The business has a 50-day moving average price of $39.35 and a 200-day moving average price of $33.48.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. The firm had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. As a group, equities analysts anticipate that Septerna will post -1.41 EPS for the current fiscal year.

Septerna Company Profile

Septerna, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address.